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Chairman : Associate Professor Dr. Seow Heng Fong 
Faculty : Medicine and Health Sciences 
The major obstacle in the study of HBV has been the inability to infect either 
animal model system in vivo or continuous cell lines in vitro due to strict virus-
host range and preferential attachment of the HBV envelope proteins onto the 
plasma membrane of human hepatocytes. The direct involvement of human 
annexin-V, a calcium dependent phospholipid - binding protein in the initial step 
of HBV infection has been reported. Over the last decade, various culture 
conditions with exogenous soluble factors have also been exploited to enhance 
HBV infection in vitro. 
The aim of this study was to establish an in vitro cell culture system that would 
continuously produce sufficient HBV by episomal replication. To facilitate the 
penetration and internalization of HBV, the expression of annexin V (A V) was 
1lJ 
enhanced using dexamethasone and by transfection of two liver cell lines, Chang 
liver and HepG2 cells. In addition, culture conditions containing (i) glucose 
supplement and dimethylsulphoxide (DMSO) (ii) glucose supplement and liver 
extract, (iii) glucose supplement, DMSO and liver extract, (iv) glucose 
supplement only and (v) human interleukin-6 (hIL-6) without glucose supplement, 
were used to determine which condition was the best for HBV infection in vitro. 
The results indicated that 10-6 M dexamethasone did not significantly upregulate 
annexin V mRNA expression in both Chang and HepG2 cell lines and Chang cells 
had higher basal levels of annexin V mRNA. The Chang cell line was more 
susceptible to HBV infection than HepG2 , before and after transfection with 
human annex in V (hA V), as well as in most of the culture conditions. Only culture 
conditions containing: (i) glucose supplement, DMSO and liver extract and (ii) 
glucose supplement and DMSO, inhibited the expression of viral protein probably 
either at transcription or translation level, without affecting the appearance of viral 
covalently closed circular (ccc) DNA. Glucose supplement in the presence of liver 
extract, and hIL-6 (without glucose supplement) supported HBV replication and 
enhanced viral protein expression. 
The establishment of an in vitro cell culture system for HBV infection is very 
important because it is an essential tool for the development of new antiviral 
strategies against hepatitis B virus infection and for studying the molecular events 
in viral replication. 
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Abstrak tesis yang dikemukakan kepada Senat Universiti Putra Malaysia sebagai 
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Pengerusi : Profesor Madya Dr. Seow Beng Fong 
Fakulti : Perubatan dan Sains Kesihatan 
Penghindaran yang utama dalam penyelidikan HBV ialah ketidakupayaan 
menjangkiti sistem model haiwan secara in vivo ataupun jujukan sel berterusan 
secara in vitro disebabkan oleh lingkaran yang sempit bagi interaksi di antara 
virus dengan perumah serta kecenderungan perlekatan protein membran luar HBV 
pada membran plasma hepatosit manusia. Pembabitan annexin-V manusia, 
sesuatu protein-fosfolipid perlekatan yang bergantung kepada kalsium secara 
langsung dalam langkah awal infeksi HBV telah dilaporkan. Di sepanjang abad 
yang lalu, pelbagai keadaan kultur dengan faktor-faktor luaran yang terlarut telah 
digunakan untuk meningkatkan infeksi HBV secara in vitro. 
Objektif utama penyelidikan ini ialah untuk menubuhkan sebuah sistem kultur sel 
secara In vitro yang akan dapat menghasilkan HBV yang mencukupi secara 
bereplikasi episomal. Untuk membantu penembusan dan kemasukan HBV, 
v 
ekspresi annexin-V telah dipertingkatkan dengan menggunakan dexamethasone 
dan transfeksi dua jujukan sel hati, sel Chang dan HepG2. Di samping itu, 
keadaan kultur yang mengandungi (i) glukos tambahan dan dimetilsulfoksida 
(DMSO), (ii) glukos tambahan dan ekstrat hati, (iii) glukos tambahan, DMSO dan 
ekstrak hati, (iv) glukos tambahan sahaja serta (v) interleukin 6 manusia tanpa 
glukos tambahan, digunakan untuk memastikan yang mana keadaan adalah paling 
baik untuk infeksi HBV secara in vitro. 
Keputusan menunjukkan 10-6 M dexmethasone tidak meningkatkan ekspresi 
mRNA annexin-V secara bererti (significantly) di dalam kedua-dua jujukan sel 
HepG2 dan Chang, dan sel Chang mengandungi paras mRNA annexin V yang 
lebih tinggi. Jujukan sel Chang adalah lebih mudah dijangkiti oleh infeksi HBV 
daripada HepG2, sebelum dan selepas transfeksi dengan annexin V manusia, serta 
di dalam kebanyakan keadaan kultur. Hanya keadaan kultur yang mengandungi: 
(i) glukos tambahan, DMSO dan ekstrat hati dan (ii) glukos tambahan dan DMSO, 
telah dipamerkan dapat melarang ekspresi protein virus berkemungkinan pada 
Iangkah transkripsi atau translasi tanpa mengganggu penimbulan DNA bulat 
tertutup berkovalen (ccc) virus. Glukos tambahan dengan kehadiran ekstrat hati, 
dan lL-6 manusia (tanpa glukos tambahan) telah dipamerkan dapat menyokong 
replikasi HBV dan meningkatkan ekspresi protein virus. 
Penubuhan sistem kultur sel secara in vitro bagi infeksi HBV adalah sangat 
penting sebab tanya merupakan alatan yang diperlukan untuk 
Vl 
memperkembangkan strategi antivirus yang baru bagi menentangkan infeksi HBV 
serta menyelidiki hal-hal molekular dalam replikasi virus. 
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1.1 General View 
CHAPTER I 
INTRODUCTION 
Hepatitis B virus (HBV), a small DNA virus that replicates via reverse 
transcription, causes acute and/or chronic hepatitis and chronically infected 
individuals are at high risk for developing hepatocellular carcinoma (HCC), one of 
the commonest malignancies in the world (Okuda, 2000). It has been estimated 
that more than 2 billion people today have been infected with the hepatitis B virus 
(HBV) (De Meyer et aI., 1 997) and about 350 million are hepatitis B surface 
antigen (HBsAg) carriers, of whom over 250 000 die annually from hepatitis B 
associated liver disease (Lok, 2000). 
The standard treatment with interferon-alpha (IFN-a.) and other cytokines 
such as thymosin a.-I are not adequate to interfere with HBV replication as HBV 
covalently closed circular (ccc) DNA is not eliminated (Locamini and Birch, 
1999). Only 1 0% to 20% of chronically HBV infected patients with reduction in 
viral load (Andreas et al., 1 999) and limitation of dose-dependent side effects 
(Carithers, 1 998) are observed during interferon-alpha therapy. Newer antiviral 
therapies using nucleoside analogues such as lamivudine, famciclovir, adefovir 
and lobucavir are unsatisfactory because short-term therapy is insufficient to clear 
viral infection but virus rebounds rapidly upon drug withdrawal, and long-term 
1 
monotherapy has been associated with resistant mutants due to the mutations in 
the HBV polymerase (Lai and Yuen, 2000). 
Only humans, chimpanzees, gibbons, certain macaca are so far known to 
be susceptible to HBV infection (Walter et a/., 1996). Recently tree shrews 
(tupaias) have also been shown to be susceptible to HBV infection but with low 
efficiency (Ren and Nassal, 2001 ). The predominant site of clinical pathology for 
hepatitis B virus is the liver. The restricted host and tissue susceptibility of HBV 
infection suggests the existence of host and liver-specific viral regulatory elements 
for HBV replication. However, the major obstacle in the study of HBV has been 
the lack of an in vitro propagation system and the lack of animal model systems 
due to strict virus-host range, restraining the overall progress towards the 
understanding of the mechanisms that dictate the biological and tissue-tropic 
aspects of the HBV infection cycle. 
Many aspects of HBV biology including HBV life cycle have been 
unravelled by studying related hepadnaviruses, such as the duck hepatitis B virus 
which is capable of in vitro infection, and the woodchuck hepatitis B virus which 
allows for the in vivo study in an animal model system. However, woodchuck 
hepatitis B virus and duck hepatitis B virus, are either difficult to keep or 
significantly different from HBY. For example, avian hepatitis B virus does not 
encode the X gene, the duck HBV receptor (Tong et ai., 1999) and coreceptor (Li 
et ai., 1999) is probably different, and the transcriptional events of woodchuck 
hepatitis B virus is distantly related to HBY. Convenient small animal models are 
2 
not avaIlable because rats and mICe are not mfectable by HBV However, cross­
specIes replIcatIon of HBV has been obtamed m hepatocytes of transgemc mIce 
(GUIdottI et ai, 1995) and tnmera mIce (nan et al , 1999) 
WIthm the last two decades, most of the In VltrO studIes of HBV 
repltcatlon have been performed by transfectmg HBV genome mto human 
hepatoblastoma cell hne HepG2 (Sells et ai, 1987), Huh-7 (Yagmuma et ai, 
1987) and rat hepatoma cell hnes (ShIh et ai, 1989) The most WIdely used are 
the HepG2 2 2 15 cell hne (Sells et ai, 1987) denved from HepG2 
hepatoblastoma cellime and HB611 derIved from the HuH6 hepatoma cell hne 
However, there are several drawbacks whIch preclude the use of these cell lmes m 
studymg some aspects of HBV bIology These drawbacks are (1) TransfectlOn 
WIth HBV genome mto the cell uses constructs contammg strong heterologous 
promoters VIral productIon m tIllS system IS mamly the result of chromosomal 
replIcatIOn and does not mImIC the natural mfectton In VlVO m whIch HBV gene 
expreSSIOn IS dnven solely by endogenous HBV promoters (2) HBV expressmg 
cell hnes contam multIple copIes of mtegrated HBV DNA whIch IS not an 
obligatory part of the HBV hfecycle and IS not reqUIred for HBV repltcatIOn 
HBV genomes are not mtegrated routmely but are mamtamed as a pool of 
epIsomal ccc DNA molecules m the nucleus of mfected cells In VlVO (3) HBV 
gene expresSIon and replIcatIon cannot be regulated and are restrIcted to the fixed 
number of mtegrated HBV genomes m stable HBV expressmg cell lmes 
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